Promptly treating prostate cancer bone metastases with the newest medication ... Through the American Cancer Society, you can connect with a patient navigator at a cancer treatment center who ...

Imagine a world where bacteria, typically feared for causing disease, are turned into powerful weapons against cancer. Thats ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

In a case report published in the World Journal of Oncology, an elderly female patient was diagnosed with mast cell leukemia (MCL), with imaging showing extensive osteoblastic metastatic lesions. MCL ...

Patients with mCRPC prostate cancer have an elevated risk of fractures due to bone metastases and use of androgen receptor pathway inhibitors (ARPI).

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...